GIP and type 2 diabetes mellitus: In T2DM patients, the effect of the glucose-dependent insulinotropic polypeptide (GIP), as well as the secretion of the glucagon-like peptide-1 (GLP-1), is diminished or absent, contributing to insulin secretion deficiency [6].